Compare J M Smucker Co (SJM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs TransMedics Group Inc — how do they compare? J M Smucker Co trades at $119.86 (market cap $12.76B), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: J M Smucker Co is far larger — about 4.7× TransMedics Group Inc's market cap, and J M Smucker Co pays a 3.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and TransMedics Group Inc for 24 Days on average.
| SJM | TMDX | |
|---|---|---|
Market Cap | $12.76B | $2.74B |
Volume | 1,300,545 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $150.42 |
52-Week Low | $89.53 | $61.99 |
Typical Hold Time | 74 Days | 24 Days |
Enterprise Value | $19.61B | $3.13B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM stock trades at $119.27, up 2.88% today, with a bullish technical signal from moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2025 results were impacted by a net loss of $1.23B. Analyst consensus is positive with a $138.23 price target, representing 16% upside potential. Recent news highlights strong execution and raised 2027 guidance, while technical indicators show support at $118 and resistance at $120.
The outlook remains cautiously optimistic with earnings momentum and raised guidance supporting upside, but investors face risks from volatile profitability, high debt levels, and competitive pressures in consumer staples. The stock offers value with reasonable P/S and EV/EBITDA multiples, though the elevated P/E ratio requires sustained earnings improvement to justify current valuation levels.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
